AP
Anand Premkumar Damani
About Anand Premkumar Damani
Data last updated:
Anand Premkumar Damani is a Director at Rajendra Chemicals Private Limited (since 2022) and Designated Partner at Synthocure Pharma Llp (since 2022). The companies operate in Chemicals and Materials and Business Services. The largest current company by reported revenue is Rajendra Chemicals Private Limited at ₹7.47 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Rajendra Chemicals Private Limited U24110MH1990PTC055997 | Director | 24 Feb 2022 | 1990 | ₹7.47 Cr (FY 2025) | Active |
| Synthocure Pharma Llp ABC-7496 | Designated Partner | 13 Oct 2022 | 2022 | Active |
Board colleagues of Anand Premkumar Damani
| Name | DIN | Company | Designation |
|---|---|---|---|
| Prem Kumar N Damani | 02050315 | Rajendra Chemicals Private Limited | Director |
| Rajendrakumar Narendrakumar Damani | 02050316 | Rajendra Chemicals Private Limited | Director |
| Manav Vimal Chandak | 10024052 | Synthocure Pharma Llp | Designated Partner |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Anand Premkumar Damani
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anand Premkumar Damani
Anand Premkumar Damani currently holds 2 directorships: Rajendra Chemicals Private Limited (Director, since 24 Feb 2022, revenue ₹7.47 Cr (FY 2025)); Synthocure Pharma Llp (Designated Partner, since 13 Oct 2022).
Anand Premkumar Damani was first appointed on 24 Feb 2022 as Director at Rajendra Chemicals Private Limited.
The current boards of Anand Premkumar Damani's companies include Prem Kumar N Damani (Rajendra Chemicals Private Limited), Rajendrakumar Narendrakumar Damani (Rajendra Chemicals Private Limited), Manav Vimal Chandak (Synthocure Pharma Llp).